Loading…
Loading…
Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Axsome Therapeutics should expand its approved lineup while not facing the threat of generic competition through 2036. Eli Lilly is a leader in its core market and could diversify its lineup over the long run.
AXSM's Auvelity sales surged 54.2% to $333 million in the first half of 2026. New indications could further expand its growth potential.
Axsome sees at least $8 billion in potential peak Auvelity sales. Additional drugs and pipeline candidates could fuel long-term growth.
AXSM, NBIX, ALKS and ACAD are advancing CNS treatments for mental health disorders, with growing product sales, pipeline progress and new growth opportunities.
Axsome Therapeutics is seeing massive revenue growth as it expands its footprint in the central nervous system treatment market. Moderna is moving beyond its pandemic roots by advancing a deep pipeline of mRNA-based vaccines and oncology therapies.
NEW YORK, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the third quarter of 2026 on Monday, November 2, 2026, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update.
Axsome Therapeutics is delivering explosive revenue growth as it scales its commercial portfolio for central nervous system disorders. Vertex Pharmaceuticals remains a highly profitable giant with absolute dominance in cystic fibrosis and expanding reach in gene therapy.